For patients with high body surface areas (BSA), differing chemotherapy dosing strategies have been utilized in attempts to reduce toxicity. In a retrospective evaluation, we compared the effects of chemotherapy dosing in acute myeloid leukemia patients with high BSA (>2 m2) who received capped doses (n = 12) to those who received uncapped doses (n = 24), and to patients with BSA ≤ 2 m2 (n = 42). There were no statistically significant differences among groups (BSA ≤ 2 m2, BSA > 2 m2 capped, and BSA > 2 m2 uncapped) in the incidences of febrile neutropenia (85.7, 66.7, and 75.0%, respectively, p = 0.29), bacteremia (19.0, 8.3, and 16.7%, respectively, p = 0.68), mucositis (42.8, 50.0, and 41.7%, respectively, p = 0.88) or nausea/vomiting (47.6, 33.3, and 37.5, respectively, p = 0.57). Results suggest delivery of unadjusted chemotherapy based on actual body weight is likely safe in hematological malignancies.
© Elsevier 2015. This post-print version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/.
Available at: http://works.bepress.com/david-reeves/11/